17 September 2020 : Clinical Research
Comparison of Clinical Outcomes in Patients with ST Elevation Myocardial Infarction with Percutaneous Coronary Intervention and the Use of a Telemedicine App Before and After the COVID-19 Pandemic at a Center in Beijing, China, from August 2019 to March 2020
Jing Nan1ABCDEG*, Shuai Meng1BCE, Hongyu Hu1CDE, Ruofei Jia1DEF, Wei Chen1DEF, Qun Li1DE, Tong Zhang1DEF, Ke Song1DEF, Yang Wang2ACDE, Zening Jin1ABCDEFDOI: 10.12659/MSM.927061
Med Sci Monit 2020; 26:e927061
Table 1 Baseline clinical characteristics of the app user group and non-app user group before and after the COVID-19 pandemic.
| Patients before the pandemic (n=183) | *p value | Patients after the pandemic (n=60) | **p value | ***p value | |||
|---|---|---|---|---|---|---|---|
| App user group (n=25) | Non App user group (n=158) | App user group (n=8) | Non App user group (n=52) | ||||
| Age (years) | 68 (51–73.5) | 66.5 (57–76) | 0.656 | 67.5 (53.25–81.25) | 71.5 (56.75–77.75) | 0.939 | 0.193 |
| Male | 13 (52%) | 100 (63.3%) | 0.376 | 5 (62.5%) | 32 (61.5%) | 1.000 | 1.000 |
| Hypertension | 8 (32%) | 108 (68.4%) | 0.001 | 4 (50%) | 20 (38.5%) | 0.702 | 0.002 |
| Diabetes | 7 (28%) | 76 (48.1%) | 0.083 | 2 (25%) | 25 (48.1%) | 0.276 | 1.000 |
| Dyslipidemia | 7 (28%) | 61 (38.6%) | 0.377 | 3 (37.5%) | 13 (25%) | 0.429 | 0.160 |
| Current smoker | 13 (52%) | 58 (36.7%) | 0.185 | 2 (25%) | 16 (30.8%) | 1.000 | 0.280 |
| Prior myocardial infarction | 5 (20%) | 18 (11.4%) | 0.325 | 2 (25%) | 6 (11.5%) | 0.288 | 0.827 |
| Prior percutaneous coronary intervention | 7 (28%) | 19 (12.0%) | 0.058 | 1 (12.5%) | 5 (9.6%) | 1.000 | 0.512 |
| Previous coronary artery bypass surgery | 0 (0%) | 1 (0.6%) | 1.000 | 1 (13.3%) | 0 (0%) | 0.133 | 0.434 |
| Previous cerebrovascular event | 5 (20%) | 42 (26.6%) | 0.625 | 2 (25%) | 4 (7.7%) | 0.178 | 0.011 |
| Chronic renal failure (estimated glomerular filtration rate <60 mL/min) | 1 (4%) | 11 (6.3%) | 1.000 | 0 (0%) | 7 (13.5%) | 0.578 | 0.265 |
| Premature CAD history | 1 (4%) | 23 (14.6%) | 0.207 | 0 (0%) | 5 (9.6%) | 1.000 | 0.369 |
| Killip classification ≥2 | 10 (40%) | 64 (40.5%) | 1.000 | 4 (50%) | 32 (61.5%) | 0.702 | 0.011 |
| Lab test | |||||||
| Peak cTn-I | 162.6±16.87 | 166.4±20.17 | 0.120 | 81.78±32.04 | 103.93±34.96 | 0.097 | 0.060 |
| BNP on admission | 303 (202.8–408) | 301.5 (197.88–410.5) | 0.969 | 328 (197.75–416) | 303 (210–408.25) | 0.913 | 0.626 |
| Left ventricular ejection fraction (%) | 47 (42–53) | 47 (40.5–52.5) | 0.541 | 46 (39.5–51.75) | 45.5 (41.25–55) | 0.711 | 0.677 |
| Baseline medication | |||||||
| Aspirin | 12 (48%) | 46 (29.1%) | 0.068 | 2 (25%) | 13 (25%) | 1.000 | 0.417 |
| ADP receptor antagonist | 1 (4%) | 9 (5.7%) | 1.000 | 1 (12.5%) | 5 (9.6%) | 1.000 | 0.235 |
| Oral anticoagulant | 4 (16%) | 30 (19%) | 1.000 | 1 (12.5%) | 16 (30.8%) | 0.420 | 0.143 |
| Statin | 7 (28%) | 59 (37.3%) | 0.502 | 3 (37.5%) | 14 (26.9%) | 0.676 | 0.347 |
| ACEI or ARB | 4 (16%) | 37 (23.4%) | 0.606 | 1 (12.5%) | 7 (13.5%) | 1.000 | 0.142 |
| β blocker | 2 (8%) | 23 (14.6%) | 0.537 | 1 (12.5%) | 2 (3.8%) | 0.354 | 0.100 |
| Frequencies are reported as n/total (%), unless otherwise specified. CAD – cardiovascular disease; BNP – B-type natriuretic peptide; ADP – adenosine diphosphate; ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker. * Comparison between App user and non-App user group after the pandemic; ** comparison between App user and non-App user group after the pandemic; *** comparison between patients before and after the pandemic. | |||||||